The Latest Cardiac and Vascular News
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in AI-powered precision cardiovascular medicine, today announced the launch of its redesigned website at CDIO.AI. This new site emphasizes the Company’s AI-first approach and innovative scalable solutions for the prevention, detection and management of cardiovascular disease, which is the leading cause of death […]
CLEVELAND – A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF). The study, “An Evidence-Based Screening Tool for Heart Failure with Preserved […]
HOPEWELL, N.J. , July 29, 2024 /PRNewswire/ — The aorta is the largest blood vessel in the body, and diseases or injury to the aorta can be life threatening. Offering the latest advance in minimally invasive surgery to restore function to damaged aortas, vascular surgeons at Capital…
Powerful generative AI software will enhance diagnostic speed, precision & patient outcomes Powerful generative AI software will enhance diagnostic speed, precision & patient outcomes
Thought leaders, trailblazers, and advocates gather to explore the forefront of discoveries and advance partnerships between medicine and technology. ATLANTA, July 29, 2024 /PRNewswire/ — The Heart Rhythm Society (HRS) is preparing for its third annual HRX event, bringing cardiovascular…
VasoGuard FDA clearance allows CorVascular to immediately begin marketing and selling devices to clinics, hospitals, and teaching institutions across US.
Elixir Medical’s DynamX Sirolimus-Eluting Coronary Bioadaptor System Granted FDA Breakthrough Device Designation for the Treatment of Symptomatic Ischemic Heart Disease
July 26, 2024 02:00 AM Eastern Daylight Time PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announces the conclusions of the futility analysis of the phase 2/3 GREEN study evaluating glenzocimab as an adjunct […]
Southlake, TX, July 26, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced an analysis published by the Innovation Value Institute (IVI) titled “Introduction of AI assisted Digital Health Technology to Improve Cardiovascular Pathway Efficiency” focused on the MyoVista® wavECG™’s potential to radically improve the cardiovascular pathway efficiency.
ATLANTA, July 25, 2024 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2024 financial results will be released on Thursday, August 8, 2024 after the market closes. On that day, the…
